New Scoring System Accurately Identifies Patients Likely to Respond to Treatment

Share this content:
Gene expression that causes chromosomal instability may predict which patients with lung or breast cancer are likely to respond to chemotherapy and radiotherapy.
Gene expression that causes chromosomal instability may predict which patients with lung or breast cancer are likely to respond to chemotherapy and radiotherapy.

Gene expression that causes chromosomal instability may predict which patients with lung or breast cancer are likely to respond to chemotherapy and radiotherapy, according to a study published in Nature Communications.1

The chromosomal locus involved in copying, the centromere, and the kinetochore, which is a protein complex involved in chromosomal movement, can cause chromosomal instability by functioning abnormally. The authors of the present study developed a “Centromere and kinetochore gene Expression Score (CES),” which scores aberrance of genetic behavior among patients with cancer.

CES values positively correlate with poor prognoses, and may predict which benefits will benefit from treatment for cancer. Patients with high CES scores may avoid unnecessary therapies that will not help them, and which cause only adverse effects.

RELATED: Air Pollution May Affect Survival of Lung Cancer

The authors claim that the ability of CES values to predict patient responses indicates that chromosomal instability is an important factor of drug resistance. Tests for CES should be employed in clinical settings to prevent unnecessary treatment, and to better target treatment options for individual patients.

Reference

  1. Zhang W, Mao JH, Zhu W, et al. Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy. Nat Commun. 2016 Aug 31. doi: 10.1038/ncomms12619 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters